Ruxolitinib for treating moderate to severe chronic graft versus host disease after an allogeneic stem cell transplant in people 28 days to 17 years (terminated appraisal). NICE technology appraisal guidance 1132
National Institute for Health and Care Excellence (NICE)
Record ID 32018015025
English
Details
Project Status:
Completed
URL for project:
https://www.nice.org.uk/guidance/ta1132
Year Published:
2026
URL for published report:
https://www.nice.org.uk/guidance/ta1132
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
England
MeSH Terms
- Stem Cell Transplantation
- Graft vs Host Disease
- Infant
- Infant, Newborn
- Child
- Adolescent
- Nitriles
- Pyrazoles
- Pyrimidines
- Janus Kinase Inhibitors
Contact
Organisation Name:
National Institute for Health and Care Excellence
Contact Address:
3rd floor, 3 Piccadilly Place, Manchester, M1 3BN
Contact Name:
nice@nice.nhs.uk
Contact Email:
nice@nice.nhs.uk
Copyright:
National Institute for Health and Care Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.